Recent News

• 06.11.2026 - Kura Oncology And Kyowa Kirin Report Encouraging Long-Term Results for Ziftomenib / 7+3 Combination In Newly Diagnosed AML
• 06.03.2026 - Kura Oncology Highlights Darlifarnib’s Potential as a Foundational Combination Platform for KRAS-Mutant Cancers and Outlines Development Strategy
• 06.02.2026 - Kura Oncology and Kyowa Kirin Announce Publication in Blood of Ziftomenib plus Venetoclax / Azacitidine Combination in Patients with R/R NPM1-m AML
• 05.26.2026 - Kura Oncology Reports Strong Clinical Activity and Safety with Darlifarnib + Adagrasib in KRAS G12C-Mutated Solid Tumors

Recent Filings

• 06.04.2026 - 4 Statement of changes in beneficial ownership of securities
• 06.04.2026 - 4 Statement of changes in beneficial ownership of securities
• 06.04.2026 - 8-K Current report
• 06.04.2026 - S-8 Securities to be offered to employees in employee benefit plans
• 06.04.2026 - 4 Statement of changes in beneficial ownership of securities
• 06.04.2026 - 4 Statement of changes in beneficial ownership of securities
• 06.04.2026 - EX-99.1 EX-99.1
• 06.04.2026 - 4 Statement of changes in beneficial ownership of securities
• 06.04.2026 - 4 Statement of changes in beneficial ownership of securities
• 06.04.2026 - 4 Statement of changes in beneficial ownership of securities